Global Muscular Dystrophy Drugs Market, By Drugs Corticosteroids, Eteplirsen, Golodirsen, Cardiovascular Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Muscular Dystrophy Drugs Market Analysis and Size
The diagnosed widespread cases of muscular dystrophy are estimated to increase in the U.S. and decrease in Japan between 2020 to 2030. In 2020, deletion mutation was the most predominant mutation among this disorder cases. The least prevalent mutation type was the splice site mutation. The U.S. represents more than 90% of the DMD sales in 2020, but its contribution is projected to decline in 2030. Steroids can treat all muscular dystrophy patient, regardless of mutation types.
Data Bridge Market Research analyses a growth rate in the global muscular dystrophy drugs market in the forecast period 2022-2029. The expected CAGR of global muscular dystrophy drugs market is tend to be around 42.2% in the mentioned forecast period. The market was valued at USD 2.13 billion in 2021, and it would grow upto USD 35.61 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Muscular Dystrophy Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Corticosteroids, Eteplirsen, Golodirsen, Cardiovascular Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Boehringer Ingelheim International Gmbh (Germany), Sanofi (France), Sarepta Therapeutics, Inc (U.K.), FibroGen, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Muscular dystrophy is a group of diseases wherein loss of muscle mass or muscle weakness occurs. In muscular dystrophy, which is a gene mutation occurs that interferes with the protein production needed for the healthy muscles. As there is no prominent cure for muscular dystrophy, medication and other therapy may decrease the symptoms. Patients suffering from this disorder have symptoms such as frequent falls, troubling in walking, jumping and running, large calf muscle among others.
Global Muscular Dystrophy Drugs Market Dynamics
Drivers
- Increased Use of Corticosteroids
Compared to the several other products, corticosteroids are possibly to evolve as the top-selling products during 2022-2029. By 2029 end, corticosteroids are anticipated to cross US$ 9,000 million revenue. Several scientific research has found that compared to several products to treat muscular dystrophy, corticosteroids helps in improving the muscle strength for up to 2-5 years. However, the long-term benefit of corticosteroids is yet a vague concept.
- Increasing Clinical Research
Currently, numerous clinical trials are being conducted to evaluate potential treatments for muscular dystrophy. The only approved pharmacological therapy for managing this condition is an anti-inflammatory regimen that is based on corticosteroids. In the recent times, there has been a huge rise in the discovery and development of pharmaceutical drugs. Around all major companies are now focusing on R&D, possibly leaving a major impact on the market in the upcoming years.
Opportunities
- Varied New Treatments
Among the numerous treatment types, exon-skipping is holding a great demand. Internal deletions in the gene for dystrophin are the major cause of muscular dystrophy. To allow the remaining exons to come altogether, one therapeutic strategy is to mask an exon near the location where the other exons are missing. For instance, in June 2022, Novartis announced, that the European Commission (EC) approved Tabrecta as a monotherapy for the treatment of adults suffering from advanced non-small cell lung cancer (NSCLC) which has mutations that cause exon 14 skipping and who require systemic therapy after receiving prior immunotherapy or platinum-based chemotherapy.
- Rising R&D and New Drug Approvals
The unmet needs of patients suffering from myelofibrosis are encouraging manufacturers to develop new solutions. The increasing investments in the R&D activities to develop a precise treatment for myelofibrosis is projected to boost the growth of the industry in the forecast period. The quick technological advancements and ongoing clinical trials contribute to industry growth. Other factors such as reimbursement policies, favourable government initiatives, improved healthcare sector, busy lifestyle and changing dietary patterns are also contributing to the industry growth.
Restraints/Challenges
- Lack of Awareness
The lack of awareness about muscular dystrophy and the unavailability of numerous awareness programs hamper the market growth.
- Insufficient Funds
The insufficient funds that are associated with the treatment processes are hampering the growth of the market. Several private and government organizations are withdrawing their funds or not providing enough funds for the high-end treatment processes impeding the market's growth.
This global muscular dystrophy drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global muscular dystrophy drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Muscular Dystrophy Drugs Market Scope
The global muscular dystrophy drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Corticosteroids
- Eteplirsen
- Golodirsen
- Cardiovascular Medication
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Muscular Dystrophy Drugs Market Regional Analysis/Insights
The global muscular dystrophy drugs market is analyzed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global muscular dystrophy drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing positive growth for global muscular dystrophy drugs market throughout the forecast period because of the increased awareness about the diseases and rapidly disposable income.
North America dominates the market because of the increase prevalence of myelofibrosis (MF), high demand of targeted therapies and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Muscular Dystrophy Drugs Market Share Analysis
The global muscular dystrophy drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global muscular dystrophy drugs market.
Key players operating in the global muscular dystrophy drugs market include:
- Pfizer Inc (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Mylan N.V. (U.S.)
- Fresenius Kabi AG (Germany)
- Hikma Pharmaceuticals PLC (Japan)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Bristol Myers Squibb Company (U.S.)
- GSK Plc. (U.K.)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd (India)
- Boehringer Ingelheim International Gmbh (Germany)
- Sanofi (France)
- Sarepta Therapeutics, Inc (U.K.)
- FibroGen, Inc. (U.S.)
SKU-